Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
Journal of Allergy and Clinical Immunology · 2023-12 · 152 (6) · 1493-1519
DOI: 10.1016/j.jaci.2023.08.030 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-12. Verfasst von Derek K Chu und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, Hamilton, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hami…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dermatologic Agents, Asthma, Eczema. Die Arbeit wurde bisher 109-mal zitiert (Crossref) und nennt 263 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Atopic dermatitis (AD) is a common skin condition with multiple topical treatment options, but uncertain comparative effects. OBJECTIVE: We sought to systematically synthesize the benefits and harms of AD prescription topical treatments. METHODS: For the 2023 American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma, and Immunology Joint Task Force on Practice Parameters AD guidelines, we searched MEDLINE, EMBASE, CENTRAL, CINAHL, LILACS, ICTRP, and GREAT databases to September 5, 2022, for randomized trials addressing AD topical treatments. Paired reviewers independently screened records, extracted data, and assessed risk of bias. Random-effects network meta-analyses addressed AD severity, itch, sleep, AD-related quality of life, flares, and harms. The Grading of Recommendations Assessment, Development and Evaluation approach informed certainty of evidence ratings. We classified topical corticosteroids (TCS) using 7 groups-group 1 being most potent. This review is registered in the Open Science Framework (https://osf.io/q5m6s). RESULTS: The 219 included trials (43,123 patients) evaluated 68 interventions. With high-certainty evidence, pimecrolimus improved 6 of 7 outcomes-among the best for 2; high-dose tacrolimus (0.1%) improved 5-among the best for 2; low-dose tacrolimus (0.03%) improved 5-among the best for 1. With moderate- to high-certainty evidence, group 5 TCS improved 6-among the best for 3; group 4 TCS and delgocitinib improved 4-among the best for 2; ruxolitinib improved 4-among the best for 1; group 1 TCS improved 3-among the best for 2. These interventions did not increase harm. Crisaborole and difamilast were intermediately effective, but with uncertain harm. Topical antibiotics alone or in combination may be among the least effective. To maintain AD control, group 5 TCS were among the most effective, followed by tacrolimus and pimecrolimus. CONCLUSIONS: For individuals with AD, pimecrolimus, tacrolimus, and moderate-potency TCS are among the most effective in improving and maintaining multiple AD outcomes. Topical antibiotics may be among the least effective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, McMaster University, Hamilton, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada; Evidence in Allergy Group, McMaster University, Hamilton…
- Department of Medicine, McMaster University, Hamilton, Canada; Evidence in Allergy Group, McMaster University, Hamilton, Canada.
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.
- Department of Medicine, McMaster University, Hamilton, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.
- Universidad de Los Andes, Bogotá, Colombia; Fundacion Santa Fe de Bogotá University, Bogotá, Colombia.
- Universidad de Los Andes, Bogotá, Colombia.
Zitieren
APA
Chu, D. K., Chu, A. W. L., Rayner, D. G., Guyatt, G. H., Yepes-Nuñez, J. J., Gomez-Escobar, L., Pérez-Herrera, L. C., Díaz Martinez, J. P., Brignardello-Petersen, R., Sadeghirad, B., Wong, M. M., Ceccacci, R., Zhao, I. X., Basmaji, J., MacDonald, M., Chu, X., Islam, N., Gao, Y., Izcovich, A., …, & Schneider, L. (2023). Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. Journal of Allergy and Clinical Immunology, 152(6), 1493-1519. https://doi.org/10.1016/j.jaci.2023.08.030
Vancouver
Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nuñez JJ, Gomez-Escobar L, et al. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. Journal of Allergy and Clinical Immunology. 2023;152(6):1493-1519. doi:10.1016/j.jaci.2023.08.030
BibTeX
@article{Chu2023,
author = {Chu, Derek K and Chu, Alexandro W L and Rayner, Daniel G and Guyatt, Gordon H and Yepes-Nuñez, Juan José and Gomez-Escobar, Luis and Pérez-Herrera, Lucia C and Díaz Martinez, Juan Pablo and Brignardello-Petersen, Romina and Sadeghirad, Behnam and Wong, Melanie M and Ceccacci, Renata and Zhao, Irene X and Basmaji, John and MacDonald, Margaret and Chu, Xiajing and Islam, Nazmul and Gao, Ya and Izcovich, Ariel and Asiniwasis, Rachel N and Boguniewicz, Mark and De Benedetto, Anna and Capozza, Korey and Chen, Lina and Ellison, Kathy and Frazier, Winfred T and Greenhawt, Matthew and Huynh, Joey and LeBovidge, Jennifer and Lio, Peter A and Martin, Stephen A and O'Brien, Monica and Ong, Peck Y and Silverberg, Jonathan I and Spergel, Jonathan M and Smith Begolka, Wendy and Wang, Julie and Wheeler, Kathryn E and Gardner, Donna D and Schneider, Lynda},
title = {Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials},
journal = {Journal of Allergy and Clinical Immunology},
year = {2023},
volume = {152},
number = {6},
pages = {1493--1519},
doi = {10.1016/j.jaci.2023.08.030}
}
EUVIMED